Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Antibiotic Resistant Infection Clear all

Conditions: Urinary Tract Infections
Interventions: Urine PCR testing; Diagnostic Test
Lead sponsor: David Sheyn; Other
Eligibility: 60 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Urinary Tract Infections, Urosepsis
Interventions: urine culture and susceptibility testing; Other
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 801 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Sylmar, California

Conditions: UTI - Lower Urinary Tract Infection, Antibiotic Resistant Infection
Interventions: Ciprofloxacin; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Bacterial Infection
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Irvine, California • Long Beach, California • Orange, California

Conditions: Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions: Cefazolin, Silberg Tissue Preparation System; Drug · Device
Lead sponsor: Sonescence, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Sebastopol, California

Conditions: Bacteremia
Interventions: Daptomycin, Vancomycin, Ceftaroline; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: La Mesa, California • San Diego, California

Conditions: HIV Infections, Tuberculosis
Interventions: Cycloserine, Ethionamide, Capreomycin sulfate, Aminosalicylic acid, Streptomycin sulfate, Ethambutol hydrochloride, Amikacin sulfate, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin, Clofazimine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 21
States / cities: Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more

Conditions: Vesicoureteral Reflux, Urinary Tract Infections
Interventions: Trimethoprim-Sulfamethoxazole, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 16 more

Conditions: Abscess
Interventions: Incision and drainage, Trimethoprim/Sulfamethoxazole (Bactrim), Placebo; Procedure · Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 6 Months to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Staphylococcal Infection
Interventions: Cephalexin, Clindamycin, Placebo, Trimethoprim-sulfamethoxazole; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 2 more

Conditions: Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
Interventions: Not listed
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Acute Otitis Media
Interventions: Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days; Drug
Lead sponsor: Alejandro Hoberman; Other
Eligibility: 6 Months to 23 Months
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Bardstown, Kentucky • Pittsburgh, Pennsylvania

Conditions: Bacterial Infections
Interventions: Merrem; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more

Conditions: Antimicrobial Resistance
Interventions: Routine Infection control; Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bacterial Infections
Interventions: Zyvox® / Linezolid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 6 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy, Sepsis, Severe, Septic Shock, Septic Syndrome
Interventions: Multifaceted de-implementation strategy to reduce vancomycin overuse; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 52,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Urinary Tract Infections, Recurrent UTI, Antibiotic Resistant Infection
Interventions: Bifidobacterium infantis, Placebo, Antibiotics; Dietary Supplement · Other · Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Jefferson, Louisiana

Conditions: Multi-antibiotic Resistance
Interventions: Multi-modal Infection Control Program; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Infectious Disease of Digestive Tract
Interventions: Lactobacillus rhamnosus GG; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Appendicitis (Diagnosis)
Interventions: Cefoxitin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: E. Coli Infection, Multi-antibiotic Resistance
Interventions: Not listed
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Staphylococcus Aureus Infection
Interventions: Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies; Combination Product · Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Whiteriver, Arizona

Search by objective public record fields.

Urine Gene Analysis for Pathogen Detection

Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs

Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Antibiotic Therapy After Incision and Drainage for Abscess

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients

Surveillance of Healthcare-associated Infections & Antimicrobial Resistance

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus

Probiotics and Multi-Drug Resistant Urinary Tract Infection

Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents

The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria

Precision Antibiotic Dosing for Appendectomy

Perinatal Transmission of MDR Bacteria

Staph Intervention for Effective Local Defense